A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
44
Participants
Timeline
Start Date
November 22, 2024
Primary Completion Date
November 22, 2026
Study Completion Date
November 22, 2026
Conditions
Kidney Failure, Chronic
Interventions
DRUG
apabetalone
RVX000222 oral (apabetalone), 100 mg capsule
DRUG
Placebos
matching placebo capsule
All Listed Sponsors
lead
Resverlogix Corp
INDUSTRY
NCT03160430 - A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis | Biotech Hunter | Biotech Hunter